A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
Purpose
The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Conditions
- Bronchopulmonary Dysplasia
- Chronic Lung Disease of Prematurity
- Intraventricular Hemorrhage
- Retinopathy of Prematurity (ROP)
Eligibility
- Eligible Ages
- Between 0 Hours and 24 Hours
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Written informed consents and/or assents must be signed and dated by the participant's parent(s) prior to any study related procedures. The informed consent and any assents for underage parents must be approved by the IRB/IEC (in accordance with local regulations). 2. Written informed consents and/or assents must be signed and dated by the participant's birth mother prior to providing study-related information related to birth mother medical history, pregnancy and the birth of the participant. The informed consent and any assents for underage birth mothers must be approved by the IRB/IEC (in accordance with local regulations). 3. Subjects must be between 23 weeks +0 days and 27 weeks +6 days GA, inclusive.
Exclusion Criteria
- Detectable major (or severe) congenital malformation identified before randomization. 2. Known or suspected chromosomal abnormality, genetic disorder, or syndrome, identified before randomization, according to the investigator's opinion. 3. Hypoglycemia at Baseline (blood glucose less than (<) 45 milligrams per deciliter [mg/dL] or 2.5 milli moles per liter [mmol/L]) which persists in spite of glucose supplementation, to exclude severe congenital abnormalities of glucose metabolism. 4. Clinically significant neurological disease identified before randomization according to cranial ultrasound (hemorrhages confined to the germinal matrix are allowed) and investigator's opinion. 5. Any other condition or therapy that, in the investigator's opinion, may pose a risk to the participant or interfere with the participant's potential compliance with this protocol or interfere with interpretation of results. 6. Current or planned participation in a clinical study of another investigational study treatment, device, or procedure (participation in non-interventional studies is permitted on a case-by-case basis). 7. The participant or participant's parent(s) is/are unable to comply with the protocol or is unlikely to be available for long-term follow-up as determined by the investigator. 8. Birth mother with active COVID-19 infection at birth or a history of severe COVID-19 infection (requiring intensive care hospitalization) during pregnancy. 9. Birth mother with known HIV or hepatitis (B, C, or E) infection.
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental OHB-607 |
Participants will receive continuous IV infusion of OHB-607 through from birth up to PMA 29 weeks +6 days. |
|
No Intervention Standard Neonatal Care |
Standard neonatal care alone will be provided. |
|
Recruiting Locations
Arkansas Children's Hospital
Little Rock 4119403, Arkansas 4099753 72202-3500
Little Rock 4119403, Arkansas 4099753 72202-3500
University of Arkansas for Medical Sciences
Little Rock 4119403, Arkansas 4099753 72202-3500
Little Rock 4119403, Arkansas 4099753 72202-3500
Children's Hospital of Orange County
California City 5332748, California 5332921 92868
California City 5332748, California 5332921 92868
Jackson Memorial Hospital
Miami 4164138, Florida 4155751 33136-1005
Miami 4164138, Florida 4155751 33136-1005
Tampa General Hospital
Tampa 4174757, Florida 4155751 33606-3571
Tampa 4174757, Florida 4155751 33606-3571
University of Illinois at Chicago
Chicago 4887398, Illinois 4896861 60612
Chicago 4887398, Illinois 4896861 60612
Riley Hospital for Children
Indianapolis 4259418, Indiana 4921868 46202
Indianapolis 4259418, Indiana 4921868 46202
Memorial Hospital of South Bend
South Bend 4926563, Indiana 4921868 46601-1078
South Bend 4926563, Indiana 4921868 46601-1078
Norton Children's Hospital
Louisville 4299276, Kentucky 6254925 40202
Louisville 4299276, Kentucky 6254925 40202
Ochsner Baptist Medical Center
New Orleans 4335045, Louisiana 4331987 70115
New Orleans 4335045, Louisiana 4331987 70115
Tufts Medical Center
Boston 4930956, Massachusetts 6254926 02111-1553
Boston 4930956, Massachusetts 6254926 02111-1553
Children's Minnesota - Children's Hospital and Clinics - St. Paul
Saint Paul 5045360, Minnesota 5037779 55102
Saint Paul 5045360, Minnesota 5037779 55102
Children's Minnesota - Children's Hospital and Clinics
Saint Paul 5045360, Minnesota 5037779 55102
Saint Paul 5045360, Minnesota 5037779 55102
University of Mississippi Medical Center
Jackson 4431410, Mississippi 4436296 39216-4500
Jackson 4431410, Mississippi 4436296 39216-4500
University of Rochester
Rochester 5134086, New York 5128638 14627
Rochester 5134086, New York 5128638 14627
Maria Fareri Children's Hospital
Valhalla 5142090, New York 5128638 10595
Valhalla 5142090, New York 5128638 10595
University of Oklahoma Health Sciences Center
Oklahoma City 4544349, Oklahoma 4544379 73104
Oklahoma City 4544349, Oklahoma 4544379 73104
Medical University of South Carolina Children Hospital
Charleston 4574324, South Carolina 4597040 29425-8908
Charleston 4574324, South Carolina 4597040 29425-8908
UVA Children's Hospital
Charlottesville 4752031, Virginia 6254928 22903
Charlottesville 4752031, Virginia 6254928 22903
Virginia Commonwealth University - Children's Hospital of Richmond at VCU
Richmond 4781708, Virginia 6254928 23298-5075
Richmond 4781708, Virginia 6254928 23298-5075
More Details
- NCT ID
- NCT03253263
- Status
- Recruiting
- Sponsor
- OHB Neonatology Ltd.